XLO: the cashflow

MyFinsight

For the quarter ending 2025-09-30, XLO had -$17,780K decrease in cash & cash equivalents over the period. -$17,495K in free cash flow.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	-16,287	-29,109
Depreciation and amortization	340	878
Stock-based compensation expense	1,123	2,886
Change in fair value of common stock warrant liabilities	15,380	50
Issuance costs allocated to common stock warrant liabilities	0	2,284
License agreement receivable	17,500	-
Prepaid and other assets	500	-3,080
Accounts payable	-1,798	1,522
Accrued expenses and other liabilities	3,312	-5,219
Deferred revenue	-1,565	38,129
Net cash used in operating activities	-17,495	14,501
Purchases of property and equipment	0	423
Net cash used in investing activities	0	-423
Proceeds from issuance of common stock under employee stock purchase plan	0	40
Proceeds from exercise of stock options	0	9
Proceeds from issuance of common stock in connection with sale of stock-Follow On Offering	-285	47,318
Proceeds from issuance of common stock in connection with stock purchase agreement, net of issuance costs-Private Placement Abbvie Inc.Stock Purchase Agreement	0	2,810
Proceeds from issuance of common stock in connection with sale of stock-At Market Offerings	0	2,017
Net cash provided by financing activities	-285	52,194
Increase in cash, cash equivalents and restricted cash	-17,780	66,272
Cash and cash equivalents at beginning of period	57,073	-
Cash and cash equivalents at end of period	105,565	-

Unit: Thousand (K) dollars